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cDepartment of Chemistry and Biochemistry, University of Lisboa, Campo Grande-C8, 1749-016 Lisboa, PortugalThe cystic fibrosis gene encodes the cystic fibrosis and its consequences for host–bacterial interactions in thetransmembrane conductance regulator (CFTR) protein whi-
cha is a 1480 amino acid, glycosylated membrane protein
that functions as a cAMP-dependent chloride (Cl) channel.
It is mainly expressed in secretory epithelia. The F508del-
CFTR protein, resultant from the mutant gene found in 70%
of CF chromosomes, is aberrantly folded, mostly blocked
for maturation and degraded in the ER by the ubiquitin
proteosome pathway. This mutant still functions as a cAMP-
dependent Cl channel to some degree if the protein is
directed to the plasma membrane by some strategy that
corrects its cellular location. The properties of wild-type and
mutant CFTR proteins are studied extensively using differ-
ent biochemical and biophysical approaches. Although these
studies are being developed for more than 15 years, many
dark areas in the research field of CFTR protein still need to
be unmasked. For example, the production of specific anti-
CFTR antibodies was one of the main problems for Western
immunoprecipitation and immunocytochemistry experi-
ments. Today, the evaluation of existing antibodies shows
that only few anti-CFTR antibodies are suitable for native
tissue analysis, but several can be used for cell line experi-
ments. The applicability of existing anti-CFTR antibodies is
discussed here [1], as well as the basic biochemical techni-
ques that are currently used for the study of CFTR protein
produced in vivo [2] and the techniques for its in vitro study
[3]. New studies based on proteomic approaches are
reviewed here [4]. These are being developed to get insights
on proteins differentially expressed in CF versus non-CF
cells/tissues or on proteins interacting with CFTR/F508del-
CFTR that may be involved in the traffic/degradation and or
activity of CFTR/F508del-CFTR.
The recent elucidation of murine CFTR nucleotide bind-
ing domain 1 (NBD1) called for a discussion and review of
the CFTR structural aspects [5]. The role of normal and
mutant CFTR on the glycosylation pattern of other proteins1569-1993/$ - see front matter D 2004 European Cystic Fibrosis Society. Publish
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1 Tel.: +351-21-751-92-33; fax: +351-21-750-00-88.light of recently published data are also discussed in this
section [6]. Novel insights on lipidic alterations in CF and
possible consequences for CF deserve our attention and are
also reported from a methodological point of view [7].
We believe that we were able to gather in this section
(often as authors in one joint manuscript) key groups in each
subarea dealt with. All articles are outlines/reviews of vari-
ous protocols available at the European Working Group on
CFTR Expression website [8] that should be used extensive-
ly as supplementary material. Our aim was to provide a series
of methodologies that hopefully will be useful to the novice
and experienced researcher alike by reducing effort and
research time of all with an interest in this field.References
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